Review of: "[Perspective] Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Type 1 Diabetes Treatment for Albumin-InsulinProducing Cells Expression"

Liqing Wang[1]

1 Texas A&M University - College Station

Potential competing interests: No potential competing interests to declare.

Comments to the author

Summary

The manuscript, titled "Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Type 1 Diabetes Treatment for Albumin-Insulin Producing Cells Expression," discusses and provides perspective comments on a recently published article in the NEJM titled "Semaglutide in Early Type 1 Diabetes."

The author first summarizes the processes and observations presented in the NEJM article. They then present three comments regarding this discovery. Lastly, they provide their perspective on the potential explanation for the treatment, suggesting that beta cell regeneration in early type 1 diabetes patients during the synergistic treatment of GLP-1 agonists with Degludec basal insulin may have contributed to the successful clinical results.

Overall, I believe their hypothesis is reasonably considered and could be tested in future trials. I look forward to seeing investigations into the underlying mechanisms. This perspective letter could be accepted with minor revisions and updates.

Comments

1. **Title:** Consider revising the title to address a minor grammar issue. Suggested revision: "Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression."

2. **Line 11, Page 2 (Background section):** The NEJM evaluates semaglutide in "early Type 1 diabetes," not specifically in "newly" diagnosed cases. Consider revising this word choice.

3. **Comment 1:** In the first to third sentences, please add references to support the points made.

4. **Comment 2:** In the second and third sentences, please add references to support the statements.

5. **Comment 3:** In the first and second sentences, please add references to validate the content.